Tech Center 1700 • Art Units: 1631 1633 1799
This examiner grants 38% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17999762 | COMPOSITIONS AND METHODS FOR EPIGENOME EDITING | Non-Final OA | The Regents of the University of California |
| 17551030 | Adeno-Associated Virus Virions with Variant Capsid and Methods of Use Thereof | Final Rejection | The Regents of the University of California |
| 17272194 | GENE THERAPY FOR THE TREATMENT OF GALACTOSEMIA | Non-Final OA | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 18009239 | METHODS FOR MANUFACTURING VIRAL VECTORS | Non-Final OA | Regeneron Pharmaceuticals, Inc |
| 18065360 | MINI-PROMOTER | Non-Final OA | Vanderbilt University |
| 16535042 | INDUCIBLE DNA BINDING PROTEINS AND GENOME PERTURBATION TOOLS AND APPLICATIONS THEREOF | Non-Final OA | Massachusetts Institute of Technology |
| 16761876 | METHODS AND COMPOSITIONS FOR CIRCULAR RNA MOLECULES | Final Rejection | The University of North Carolina at Chapel Hill |
| 14596051 | METHOD FOR INDUCING CELLS TO LESS MATURE STATE | Non-Final OA | Minerva Biotechnologies Corporation |
| 19087070 | POLY-DONOR CD4+ T CELLS EXPRESSING IL-10 AND USES THEREOF | Final Rejection | TR1X, INC. |
| 18327651 | CHIMERIC TRANSMEMBRANE PROTEINS AND USES THEREOF | Non-Final OA | Kite Pharma, Inc. |
| 18517080 | COMPOSITIONS AND METHODS OF TREATING USHER SYNDROME III | Non-Final OA | CASE WESTERN RESERVE UNIVERSITY |
| 18173485 | METHODS FOR ENHANCING ANTI-TUMOR ACTIVITY OF EXHAUSTED T CELLS | Non-Final OA | FRED HUTCHINSON CANCER CENTER |
| 18296623 | METHOD FOR GENERATING T CELLS PROGENITORS | Final Rejection | Institut National de la Santé et de la Recherche Médicale (INSERM) |
| 17178972 | GENERATING GABAergic NEURONS IN BRAINS | Non-Final OA | The Penn State Research Foundation |
| 17046807 | ANTI-AGING COMPOSITIONS AND METHODS OF USE | Final Rejection | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. |
| 17763122 | NOTCH RECEPTORS WITH ZINC FINGER-CONTAINING TRANSCRIPTIONAL EFFECTOR | Non-Final OA | Trustees of Boston University |
| 18191790 | AAV-BASED GENE THERAPY FOR MULTIPLE SCLEROSIS | Final Rejection | University of Florida Research Foundation, Incorporated. |
| 16933773 | NUCLEIC ACID PURIFICATION | Final Rejection | ZYMO RESEARCH CORPORATION |
| 16645213 | STEM CELL DERIVED FROM NEONATAL PIG AND METHOD FOR PRODUCING SAME | Final Rejection | OTSUKA PHARMACEUTICAL FACTORY, INC. |
| 17592335 | MRNA THERAPY FOR THE TREATMENT OF OCULAR DISEASES | Non-Final OA | Translate Bio, Inc. |
| 17897878 | LIPID NANOPARTICLE FORMULATIONS FOR CRISPR/CAS COMPONENTS | Final Rejection | Intellia Therapeutics, Inc. |
| 18041371 | CULTURED TISSUE AND BIOREACTOR SYSTEMS AND METHODS FOR PRODUCTION THEREOF | Non-Final OA | Trustees of Tufts College |
| 15282905 | COMPOSITIONS AND METHODS FOR ALTERING GENE EXPRESSION | Final Rejection | Whitehead Institute for Biomedical Research |
| 18533474 | REPLICATIVE MINICIRCLE VECTORS WITH IMPROVED EXPRESSION | Non-Final OA | ALDEVRON, L.L.C. |
| 18512933 | CANCER-KILLING CELLS | Final Rejection | LIFT BIOSCIENCES LTD |
| 18486941 | Methods of Treating Human X-Linked Retinoschisis Using Gene Therapy | Non-Final OA | TEAMEDON INTERNATIONAL, INC. |
| 17773416 | Recombinant CDKL5 Proteins, Gene Therapy and Production Methods | Non-Final OA | Amicus Therapeutics, Inc. |
| 18467037 | TRANS-SPLICING METHODS AND COMPOSITIONS FOR GENERATION OF SINGLE SEX OFFSPRING | Non-Final OA | JFL CAPITAL MANAGEMENT, LLC |
| 18156184 | Oncolytic Vaccinia Virus | Final Rejection | Queen Mary University of London |
| 16605740 | OPTIMIZED LENTIVIRAL VECTOR FOR XLA GENE THERAPY | Non-Final OA | Seattle Children's Hospital (dba Seattle Children's Research Institute) |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy